Diligence memo · auto-generated · as of July 3, 2026
Pyxis Oncology, Inc.
Pyxis Oncology, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Pyxis Oncology, Inc. operates in Pharma, based in Cambridge.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pyxis Oncology, Inc. has raised $194M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $172M on 2021-03-05.
Most recent recorded round closed around 2021-03-05.
Valuation (modeled)modeled
Provath models Pyxis Oncology, Inc. at approximately $5.0B (range $821M–$10.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.17× the median modeled value of Series D+ Pharma companies in 2019–2021 (9 peers) — value vs value, same stage and era. Within the normal band (117% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 5.3 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 7.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 96% of Pharma peers (310 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Century Therapeutics, Inc., iTeos Therapeutics, Inc., SpringWorks Therapeutics, Inc., Nurix Therapeutics, Inc., Pear Therapeutics, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.